The Federal Trade Commission has taken its fight against reverse-payment settlements in the pharmaceutical industry to two deals with no direct cash payment.
In a redacted complaint filed Wednesday, the FTC argued Endo Pharmaceuticals improperly orchestrated the delay of generic versions of its products Opana ER and Lidoderm in exchange for the promise that it would delay its own entry of the drugs to the generic market.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
